AVR.ASX: Quarterly Results Announcement and SEC Form 10-Q

Quarterly Results Announcement and SEC Form 10-Q

Stock	Anteris Technologies Ltd (AVR.ASX)
Release Time	13 Nov 2025, 9:24 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Anteris Technologies Reports Q3 2025 Results

Key Points

Ongoing development of DurAVR® THV and preparation for Pivotal Trial
Net proceeds of $80M from IPO used for development and corporate purposes
Payments to related parties of $515K in Q3 2025

Full Summary

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) announced its quarterly results for the period ended September 30, 2025. The company filed its Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission, which includes the condensed consolidated financial statements prepared in accordance with U.S. GAAP. Key highlights from the quarter include the ongoing development of the DurAVR® Transcatheter Heart Valve (THV) and the preparation for the Pivotal Trial of DurAVR® THV for treating severe aortic stenosis, using $52.7M of the net proceeds from the company's $80M IPO in December 2024. The remaining $18.3M in net proceeds were used for debt repayment, working capital, and other general corporate purposes. During the third quarter of 2025, the aggregate amount of payments to related parties and their associates, which includes director fees, company secretarial fees, and executive remuneration, was $515 thousand.